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 Nine patients with malignant esophageal obstruction were 
treated with non-covered or covered Ultraflex stents. All 
patients achieved palliation, six of nine patients showed im-
provement of at least one dysphagia grade, and five patients 
could tolerate a normal or near-normal diet. Major (massive 
bleeding) and minor complications (ingrowth, overgrowth, 
stent migration, and bleeding) were encountered during 
follow-up in 2 and 4 patients, respectively. Ultraflex stents 
for esophageal cancer offer effective palliative treatment 
and quickly improve dysphagia. However, care should be 
exercised particularly of potentially serious life-threatening 
complications such as massive bleeding.
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Introduction 
 Most patients with carcinoma of the esophagus present 
with progressive, unrelenting dysphagia, malnutrition, 
and weight loss (1). Palliative therapy is the primary 
form of treatment, since these patients are not candidates 
for curative surgical resection (2). Laser surgery, radio-
therapy and conventional plastic prostheses are well-
established modes of treatment, and highly effective 
methods of palliation for the dysphagia that usually
accompanies esophageal cancer (3-5). Laser therapy is 
not suitable for tumors causing extrinsic compression 
or long stenosis (6), while radiotherapy requires a long 
course extending at least for two months (7). Further-
more, the use of rigid plastic endoprotheses is plagued 
by high complication rates (8, 9). 
 Recently, self-expanding metal stents have provided 
a new option for the palliative treatment of malignant 
stenotic esophageal tumors (10-13). These stents have 
proved to be effective in reducing morbidity and mor-
tality (10, 11). Several studies have examined the thera-
peutic benefits of various self-expanding metal esophag-
eal stents for esophageal neoplasia, but few have com-
pared different self-expanding metal stents (12, 13). 
 The aim of the present study was to evaluate the 
effectiveness and complications of non-covered and/or 
covered Ultraflex stents for palliation of dysphagia due 
obstructive esophageal cancer.
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Patients and Methods 
Patients 
 From January 1995 to December 1997, nine patients 
with malignant dysphagia due to esophageal carcino-
mas were treated with non-covered or covered Ultraflex 
stents (Boston Scientific Corporation, Watertown, MA, 
USA) after informed consent. The mean age was 65 
years (range, 46 to 85 years) and patients included 
four men and five women. All nine patients had esophag-
eal squamous carcinomas. The tumor was located in 
the upper, middle and lower esophagus in 1, 6, and 2
patients, respectively. Chemotherapy was performed in 
3 patients, radiotherapy in 2 patients, and both in 1 
patient (Table 1).
Table 1. Patient demographics 
Cases Age Sex Location Prior treatment 
1 60 M Middle Chemotherapy 
2 62 M Middle Chemotherapy 
3 70 M Middle Chemotherapy 
4 72 F Lower None 
5 46 M Lower None 
6 56 F Upper Chemotherapy and radiation 
7 74 F Middle Radiation 
8 85 F Lower None 
9 85 F Lower Radiation
Stents placement technique 
 After guidewire insertion (Jegwire; 0.035 inch: Boston 
Scientific Corporation)esophageal dilation was performed 
twice each for 2 min using 8-10 atm Endoscopy Dilators 
(diameter 8 mm, length 50 mm, Boston Scientific Corpo-
ration). The stent was then pushed out of the delivery 
catheter and delivered. Five non-covered and six cov-
ered Ultraflex stents were implanted in these patients. 
The body of the stent ranged in length from 10 to 15 
cm (Fig. 1 A and B). The stents were placed fluoroscopic-
ally under local anesthesia. Patients underwent a follow-
up endoscopic examination immediately, 3 days, 1 week 
and 4 weeks later, and as needed thereafter.
Severity of dysphagia and complications 
 The severity of dysphagia was quantified with a 0 
to 4 dysphagia scale as follow: grade 0, normal, no 
dysphagia; grade 1, unable to swallow solid food; grade 
2, unable to swallow semi-solids; grade 3, unable to swal-
low liquids; grade 4 unable to swallow own saliva. All 
nine patients had severe grade 3 or 4 dysphagia, and 
none were suitable candidates for operative surgery. 
 The major stent-related complications were defined as 
life-threatening complications, such as bleeding requiring 
blood transfusion, while minor complications were de-
fined as non-life-threatening complications, such as tumor 
ingrowth, overgrowth, stent migration, and bleeding 
without requiring blood transfusion.
Results 
 Stent placement was successful in all nine patients, 
however two patients required a second stent because 
of migration, and tumor ingrowth or overgrowth. After 
one week of stenting, all five patients with non-covered 
stent and five of six patients with covered stent showed
Fig 1. Ultraflex stents. A; non-covered type, B; covered type 
improvement of at least one dysphagia grade. After one 
month, three patients with non-covered stent and three 
patients with covered stent became able to swallow 
a normal or near-normal diet. There was no difference 
in improvement of grades of dysphagia between non-
covered and covered Ultraflex stents. 
 Five patients were discharged from the hospital after 2 
to 4 weeks, however all nine patients died during the 
follow-up period; the mean survival after the procedure 
was 12 weeks (range 1 to 56 weeks). Severe complica-
tions, such as massive bleeding occurred in two pa-
tients who received non-covered and covered Ultraflex 
stents. Both (Case 3; non-covered and Case 9; covered) 
died due to massive esophageal bleeding, one and three 
months later, respectively. Three types of minor prob-
lems were encountered: ingrowth and overgrowth (1 
patient; non-covered type), stent migration (1 patient; 
covered type), and bleeding (2 patients; non-covered 
type). One patient (Case 8) underwent an additional 
non-covered Ultraflex stent because of stent migration 
10 days after stenting of the covered type. Another
patient (Case 2) had recurrent dysphagia due to tumor 
ingrowth and overgrowth, one after 2 months. In this 
patient, an additional overlapping covered Ultraflex stent 
was successfully placed. 
 Fig. 2 represents a 70-year old man with squamous cell
Fig 2. Endoscopic photographs. A; Nodular tumors with near-
total obstruction. B; Proximal view of non-covered Ultraflex 
stent with massive fibrin exudate after 3 days of insertion. C; 
View of non-covered Ultraflex stent with full expansion after 
7 days of application.
carcinoma of esophagus and thoracic aortic aneurysm 
(Case 3, Tables 1 and 2). Dysphagia was of grade 3. The 
patient was treated palliatively with Ultraflex stent. 
After stenting, the severity of dysphagia improved and 
the patient was able to swallow a semi-solid diet. Improve-
ment was sustained for 1 month but he suddenly died 
because of a massive hematemesis probably due to 
rupture of an aortic aneurysm. Unfortunately, autopsy 
was not performed.
Discussion 
 A variety of esophageal endoprosthesis ranging from 
rigid plastic devices to the newer self-expandable me-
tallic stents (e.g., Z-stent, Wall-stent, Ultraflex-stent) have 
been used (4, 8-33). Despite the good results, complica-
tions are common, and further therapeutic interventions 
are necessary in a considerable number of patients. Thus, 
the ideal stent is not yet available. Self-expanding me-
tallic stents offer a number of advantages, including 
small delivery systems and large lumen diameter, less 
operative sedation, ease of insertion, immediate relief of 
obstruction, and long patency rates (14, 15). Despite 
these favorable results, there are still considerable num-
ber of complications including stent migration, tumor 
ingrowth and overgrowth, and bleeding. The rate of 
complications is reported at 31-49% in patients treated 
with Z-stent and/or Wall stent (16-18). 
 Recent reports have indicated the long-term effective-
ness of Ultraflex stents and that these stents provide a 
safe method of palliative therapy for patients with ob-
structive esophageal neoplasms (12, 19). Ultraflex stents 
seem to offer a lower force of expansion (20), and Ell 
et al. (21) reported that the expansile force of Ultraflex 
stent is sufficient even for very firm strictures. However, 
in our experience, one of nine patients showed an in-
sufficient degree of spontaneous expansion. 
 The most common cause of recurrent dysphagia is 
ingrowth or overgrowth of non-covered stents by the 
tumor tissue (22, 23). Knyrim et al. (24) indicated that 
non-covered stent are associated with fewer complica-
tions. Non-covered stents are associated with tumor in-
growth and overgrowth which may further reduce the 
size of the available lumen, and sometimes require a 
second stent (stent in stent) or laser therapy (15, 25). 
Covered metallic stents offer effective treatment for per-
forations and fistulas in patients with esophageal ma-
lignancies (26,27), and might prevent tumor ingrowth 
allowing treatment of digestive-respiratory fistulas (28). 
However, preliminary studies indicate that migration of 
stent or disruption of the membrane by tumor ingrowth 
may occur even in these stents (29, 30). We presented
two cases of tumor overgrowth after stenting in pa-
tients with inoperable esophageal cancers that were 
managed by placement of a second stent. The frequency 
of distal migration of covered stents (5-25 %) is rela-
tively higher than that of non-covered stents (0-1%) 
(12, 21, 31-33). In our series, one case treated with 
covered stent later showed stent migration. 
 den Hartog et al. (34) and Kinsman et al. (35) reported 
that chemoradiotherapy increased the incidence of stent-
related complications in the management of malignant 
esophageal strictures. However, Raijman et al. (5) re-
ported that the same therapy was not associated with 
increased risk of life threatening complications. In our 
series, chemotherapy and/or irradiation before stent 
application were not associated with increased risk of 
complications (Table 2). 
 Issues related to the palliative therapy for esophageal 
cancer are complex. Whereas the tendency is to focus on 
technical aspects of therapy and the relief of dysphagia,
broader aspects related to quality of life cannot be ig-
nored (23). In our departments, patients were actively 
encouraged to take optimal oral nutrition, before and 
after discharge from hospital. Prolonged cachexia re-
duces appetite and restoration of a normal diet may 
require more than simply the restoration of the eso-
phageal lumen. 
 Further investigation in a large series of patients 
treated by stent insertion have to be performed before 
a general conclusion can be drawn regarding the clini-
cal efficacy of Ultraflex stents for endoscopic palliation 
of esophageal carcinoma. 
 In summery, Ultraflex stents for esophageal cancer 
offer a quick improvement of dysphagia in patients with 
non-operable esophageal tumors. Tumor ingrowth and 
overgrowth are problems associated with noncovered 
stent. Covered stent are associated with markedly less 
tumor ingrowth and overgrowth, but stent migration 
of covered stent is inferior to that of non-covered stents.
Table 2. Results and complications of Ultraflex stent 
Cases Stent Dysphagia grade complications Follow up 
       type Pre-stent Post(1w) Post(Imo) 
1 N 4 3 3 Bleeding Died(2mo) 
2 N 4 2 1 Ingrowth, Overgrowth Died(13mo) 
       C 3 1 1 
3 N 3 1 1 Massive bleeding Died(lmo) 
4 N 4 3 3 Bleeding Died(4mo) 
5 C 4 3 None Died(3w) 
6 C 4 4 None Died(lw) 
7 C 3 3 1 None Died(9mo) 
8 C 4 2 Stent migration Died(5mo) 
       N 2 1 1 
9 C 3 3 2 Massive bleeding Died(4mo) 
        N : non-covered type, C : covered type
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